Trials / Not Yet Recruiting
Not Yet RecruitingNCT06397274
Stemchymal® for Polyglutamine Spinocerebellar Ataxia
A Phase II, Randomized, Double-Blind, Placebo-controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of PolyQ Spinocerebellar Ataxia
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Steminent US, Inc. · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Stemchymal | Patients will receive Stemchymal® through intravenous infusion |
| BIOLOGICAL | Placebo | Patients will receive Placebo through intravenous infusion |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2024-05-02
- Last updated
- 2024-05-02
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06397274. Inclusion in this directory is not an endorsement.